‘CURE Expert Connections®’ Presents ‘Overcoming the Odds,’ a Video Series Outlining the Journey of a Stage 4 Renal Cell Cancer Survivor

On July 30, 2019 CURE Media Group — which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates and research — reported that it has launched a seven-episode discussion series featuring Steven Gallant, who shares his story of survival with stage 4 renal cell cancer (RCC), alongside Karl J. D’Silva, M.D., medical oncologist, hematologist and medical director at Lahey Cancer Center (Press release, CURE, JUL 30, 2019, View Source [SID1234537909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to launch this video series," said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. "It is revitalizing to experience Gallant’s triumph over RCC as his story is shared with both D’Silva and the audience."

Throughout the series, Gallant and D’Silva discuss Gallant’s journey to overcome this aggressive and metastatic disease, specifically with cabozantinib treatment. The first episode delves into Gallant’s diagnosis with stage 4 RCC, and the following episodes explore a variety of effective measures to manage toxicities when treating RCC. Topics of the seven-episode series include advice for patients with RCC, as well as the impact of support networks and multidisciplinary care. The series goes beyond Gallant’s personal narrative with stage 4 RCC, as D’Silva offers insight into frontline treatment options, toxicity management with cabozantinib and the typical prognosis of RCC.

Offering advice to individuals who may find themselves in similar situations, Gallant noted, "Whenever you go to the hospital, you should be positive, never feel like a victim. That victim mentality just creates a negative flow in the body. So, I went thinking I had kidney stones. I didn’t think it was a big deal. And when they diagnosed me, as they did, I still really didn’t blink because I’m such a positive person. I just stayed positive, and I believed that whatever was going to happen was the way it was supposed to be. And as it happened, it was synchronistic because of how I ended up with (D’Silva) as a doctor."

"CURE Expert Connections" is a video platform designed specifically for patients with cancer featuring information, stories and advice about the cancer journey.

To view the complete video series, click here.

About CURE Media Group

CURE Media Group is the leading multimedia resource for cancer updates

Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019

On July 30, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights (Press release, Personalis, JUL 30, 2019, View Source [SID1234537908]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 5981178. The live webinar of the call may be accessed by visiting the Events section of the company’s website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.

ONCOTELIC’S PATENTED LEAD ANTI-CANCER DRUG CANDIDATE AS WELL AS DRUG DELIVERY PLATFORM FOR BRAIN TUMORS ON TRACK FOR ADVANCED PIVOTAL PHASE 3 CLINICAL TESTING

On July 30, 2019 Oncotelic Inc. ("Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, reported that its team members will participate and provide clinical development updates at upcoming medical-scientific conferences regarding the clinical development plans for the portfolio drugs OT101 (target: brain tumors) and OXi4503 (target: leukemias) aimed at their regulatory approval (Press release, Oncotelic, JUL 30, 2019, View Source [SID1234537907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OT101, a first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of TGF-b2, is Oncotelic’s lead anti-brain tumor drug candidate. OT101 has been granted orphan designation by the FDA under the Orphan Drug Act (ODA). ODA provides for granting special status to a drug to treat a rare disease or condition upon request of a drug company. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing.

In October 2019, Dr. Vuong Trieu, Ph.D., co-founder, President and Chief Executive Officer of Oncotelic will deliver a keynote speech at the Global Congress on Pharmacology and Therapeutics in Paris, France. His presentation will focus on the anti-sense platform for drug development and the Oncotelic pipeline of RNA therapeutics, including OT101. Dr. Trieu will also attend the October 2019 Medicinal Chemistry Strategy Meeting US West Coast that will be held in San Francisco, California to lead an executive roundtable discussion about the integration of artificial intelligence (AI) and machine learning algorithms in new drug discovery and lead optimization, design of biomarker-driven clinical studies as well as identification of biomarker-enriched patient populations most likely to respond to new anti-cancer drug candidates, such as OT101. Dr. Trieu explained: "We decided to actively engage and invest in AI because it has the potential to streamline our clinical development strategy for the portfolio drug candidates by amplifying our knowledge and understanding of the target diseases, their biology as well as structural and pharmacologic characteristics of the lead compounds."

In October 2019, Oncotelic team will also attend the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in Boston, Massachusetts. "I look forward to sharing our Phase II clinical data on our first-in class RNA therapeutic for brain tumors as well as our patented Convection-Enhanced Delivery (CED) system with our collaborators and other participating physicians and scientists," said Dr. Fatih Uckun, MD, PhD the Chief Medical Officer of Oncotelic and Mateon who is responsible for the clinical development of the drug portfolio.

The Oncotelic CED platform appears to be the only reported platform that allows for the delivery of a brain tumor drug directly into the patients’ tumors via an extended continuous infusion for repeated treatment cycles for up to 6 months. Other CED systems in clinical development allow only short-term drug delivery for days to a few weeks.

Dr. Uckun explained: "Our enabling CED platform uniquely allows the personalized intratumoral delivery of immuno-oncology drugs designed to overcome the profound immunologic exhaustion and suppression in brain tumors. The insights and lessons learned from our clinical use of this CED platform in 90 high-grade glioma patients will not only inform our Phase III clinical study, but they may also provide the foundation for strategic alliances with other immune-oncology companies who are interested in using CED to explore the clinical potential of their lead therapeutic drug candidates for brain tumors."

In November 2019, Oncotelic will attend the 24th Annual Meeting of the Society for NeuroOncology in Phoenix, Arizona to report on the safety and efficacy of OT101 along with a multivariate analysis of predictive parameters for favorable overall responses and prolonged survival outcome. "The durable objective responses achieved in patients with recurrent/refractory high-grade gliomas, including GBM (WHO Grade 4) and AA (WHO Grade 3) after treatment with our lead compound OT-101 contribute to our optimism that new treatment strategies leveraging this first-in-class RNA therapeutic may favorably change the therapeutic landscape for difficult-to-treat brain tumors with a very poor prognosis," Dr. Uckun explained.

Dr. Uckun will also present a plenary talk at the 2ndInternational Precision Medicine Conference in Baltimore, Maryland. "Our recent bioinformatics research has revealed that the TGFβ2 gene product may serve as a target for immunotherapy in pediatric high-grade gliomas DIPG and GBM as well. These target validation data extend the clinical data on the therapeutic activity of OT101 in adults and young adults and further demonstrate the potential of OT101 as a promising immune-oncology drug in the treatment of pediatric high-grade gliomas DIPG and GBM, orphan diseases with a low survival rate and no established or effective standard of care," Dr. Uckun commented.

The safety and clinical potential of the lead anti-leukemia drug candidate OXi4503 was evaluated as part of a 2-drug combination regimen in a multi-institutional Phase IB clinical study at 4 academic centers in the USA. 29 relapsed/refractory acute myeloid leukemia (AML) and myeloid dysplastic syndrome (MDS) patients were evaluated and objective responses – including 4 complete responses – as well as extended survival were observed in some of the patients. These results will be presented by Dr. Uckun during the 3rd International Hematologists Summit in Saint Petersburg, Russian Federation, as part of his invited plenary talk. FDA granted orphan status as well as fast-track designation to OXi4503 for AML. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and address unmet medical need. Once an investigational agent receives Fast Track designation, early and frequent communication between FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication allows potential issues to be resolved quickly and as they arise, often leading to earlier drug approval and access by patients.

About OT101

High-grade gliomas are characterized by a T-cell exhaustion signature and pronounced T-cell hyporesponsiveness of their tumor microenvironment (TME). Transforming growth factor beta 2 (TGFb2) has been implicated as a key contributor to the immunosuppressive landscape of the TME in high-grade gliomas. OT-101, a TGFb2-specific first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of TGFb2. In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induces durable complete and partial responses in recurrent and refractory adult high-grade glioma patients, including adults with GBM.

About OXi4503

OXi4503 (combretastatin A1-diphosphate or CA1P) is a dual-mechanism vascular disrupting agent. In preclinical and clinical studies, it has been observed to compromise the tumor vasculature, resulting in extensive tumor cell death. OXi4503 is being developed as a drug candidate for relapsed/refractory AML. In addition to Fast Track status, OXi4503 has been granted orphan drug designation for the treatment of AML in both the USA and Europe.

BioLineRx to Report Second Quarter 2019 Results on August 6, 2019

On July 30, 2019 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, reported it will release its unaudited financial results for the quarter ended June 30, 2019 on Tuesday, August 6, 2019, before the US markets open (Press release, BioLineRx, JUL 30, 2019, View Source [SID1234537906]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call on Tuesday, August 6, 2019 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0644 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until August 8, 2019; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.

Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019

On July 30, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, reported that it will host a conference call and webcast to report its second quarter 2019 financial results and provide a corporate update on Tuesday, August 6, 2019 (Press release, Audentes Therapeutics, JUL 30, 2019, View Source [SID1234537905]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be held at 4:30 pm ET. To access a live webcast of the conference call, please visit the Events & Presentations page within the Investor + Media section of the Audentes website at www.audentestx.com. Alternatively, please call (833) 659-8620 (U.S.) or (409) 767-9247 (international) and dial the conference ID# 4244738 to access the call.

A replay of the live webcast will be available on the Audentes website for approximately 30 days.